microRNAs and their therapeutic strategy in phase I and phase II clinical trials

被引：11

作者：

Ameya, K. P. ^{[1
]}

Kaliaperumal, Kumaravel ^{[2
]}

Sekar, Durairaj ^{[1
]}

机构：

[1] Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, RNA Biol Lab, Chennai 600077, India

[2] Saveetha Univ, Saveetha Dent Coll, Dept Orthodont, Unit Biomat Res, Chennai 600077, Tamil Nadu, India

来源：

EPIGENOMICS | 2024年 / 16卷 / 04期

关键词：

clinical trials; diseases; miRNAs; miRNA therapeutics; signaling pathway; CANCER; DELIVERY; BIOMARKERS; PATHWAY; DISEASE; DRUG;

D O I：

10.2217/epi-2023-0363

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

miRNAs play a crucial therapeutic role in diseases such as cancer, diabetes and viral infections, with around 1900 identified in the human genome. Some have progressed to clinical trials, and miRNA mimics and miRNA inhibitors are pivotal therapeutic molecules undergoing evaluation. The review delves into various miRNA-associated clinical trials, emphasizing their precision in targeting specific genes, modulating disease pathways and diagnostic potential. This underscores the importance of miRNA therapy, foreseeing innovations in precision medicine techniques for diverse diseases. The future envisions improved delivery systems addressing challenges like immunogenicity and digestion, while a comprehensive miRNA-based omics database could guide the development of tailored antisense miRNAs, further advancing precision medicine strategies.

引用

页数：14

共 50 条

[41] Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.
Nurgat, Z
PHARMACOTHERAPY, 2005, 25 (10): : 1468 - 1468
[42] DESIGN OF PHASE-I AND PHASE-II CLINICAL-TRIALS IN CANCER - A STATISTICIANS VIEW
GELLER, NL
CANCER INVESTIGATION, 1984, 2 (06) : 483 - 491
[43] Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer
Leal, Alexis D.
Krishnamurthy, Anuradha
Head, Lia
Messersmith, Wells A.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (11) : 901 - 916
[44] Preclinical and phase I and II trials of rituximab
Maloney, DG
SEMINARS IN ONCOLOGY, 1999, 26 (05) : 74 - 78
[45] Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
Noonan, Anne
Pawlik, Timothy M.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (11) : 941 - 949
[46] Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
Scheen, Andre J.
Paquot, Nicolas
Lefebvre, Pierre J.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (12) : 1373 - 1389
[47] Sequential or combined designs for Phase I/II clinical trials? A simulation study
Rossoni, Caroline
Bardet, Aurelie
Geoerger, Birgit
Paoletti, Xavier
CLINICAL TRIALS, 2019, 16 (06) : 635 - 644
[48] Application of Bayesian hierarchical models for phase I/II clinical trials in oncology
Yada, Shinjo
Hamada, Chikuma
PHARMACEUTICAL STATISTICS, 2017, 16 (02) : 114 - 121
[49] A tool for assessing adverse events in phase I/II oncology clinical trials
Coombes, M.
Mukherjee, S.
Kowaleski, B.
Levine, M.
Cosby, J.
Arnold, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[50] Phase I and II Clinical Trials on Recombinant H. pylori Vaccine
Zou, Quan-ming
Zeng, Ming
Zhu, Feng-cai
Mao, Xu-hu
Tong, Wen-de
Guo, Gang
Lu, Dong-Shui
FASEB JOURNAL, 2008, 22

← 1 2 3 4 5 →